ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe’s Most Competitive Science Region

The Accelerator will keep U-Protein Express in pace with in contract research business by giving 3-4 times current capacity.

ImmunoPrecise Antibodies Will Join J.P. Morgan Healthcare Conference Week January 13-16, 2020.

The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry.

ImmunoPrecise Announces Record Quarterly Revenue and Significantly Expands Gross Margins

Revenue ImmunoPrecise achieved a 16% rise in revenue for the three-month period.

Talem Therapeutics accesses the OmniAb platform from Ligand Pharmaceuticals.

Talem has the right to develop and partner fully human antibodies in OmniRat®, OmniFlic®, OmniMouse®, OmniChicken®, and OmniClic™.

ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

Mr. Lundstrom has established global business leadership in transgenic animals for discovery of human therapeutic antibodies with Ligand Pharmaceuticals Inc.

Items 1 to 6 of 75 total

Show per page